Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Diabetes, Obesity and Metabolism Année : 2017

Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes

Guillermo Umpierrez
  • Fonction : Auteur
David O'Neal
  • Fonction : Auteur
Andres Digenio
  • Fonction : Auteur
Ronald Goldenberg
  • Fonction : Auteur
Eric Hernandez-Triana
  • Fonction : Auteur
Jay Lin
  • Fonction : Auteur
Cheol-Young Park
  • Fonction : Auteur
Boris Kovatchev
  • Fonction : Auteur

Résumé

Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic variability (GV) vs placebo as add-on to basal insulin. The main outcome GV measures were standard deviation (s.d.), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG) level, area under the curve for fasting glucose (AUC-F), and high (HBGI) and low blood glucose index (LBGI). The change in GV metrics over 24 weeks and relationships among baseline GV, patient characteristics and outcomes were assessed. Data were pooled from 1198 patients (665 LIXI, 533 placebo). Values for s.d., MAG level, MAGE, HBGI, and AUC-F significantly decreased with LIXI vs placebo, while LBGI values were unchanged. Higher baseline GV measures correlated with older age, longer type 2 diabetes duration, lower body mass index, higher baseline glycated/haemogobin, greater reduction in postprandial glucose (PPG) level, and higher rates of symptomatic hypoglycaemia. These data show that LIXI added to basal insulin significantly reduced GV and PPG excursions vs placebo, without increasing the risk of hypoglycaemia (LBGI).

Dates et versions

hal-01778360 , version 1 (25-04-2018)

Identifiants

Citer

Guillermo Umpierrez, David O'Neal, Andres Digenio, Ronald Goldenberg, Eric Hernandez-Triana, et al.. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19 (9), pp.1317 - 1321. ⟨10.1111/dom.12930⟩. ⟨hal-01778360⟩
34 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More